作者
Shaji K Kumar, Susanna J Jacobus, Adam D Cohen, Matthias Weiss, Natalie Callander, Avina K Singh, Terri L Parker, Alexander Menter, Xuezhong Yang, Benjamin Parsons, Pankaj Kumar, Prashant Kapoor, Aaron Rosenberg, Jeffrey A Zonder, Edward Faber, Sagar Lonial, Kenneth C Anderson, Paul G Richardson, Robert Z Orlowski, Lynne I Wagner, S Vincent Rajkumar
发表日期
2020/10/1
期刊
The Lancet Oncology
卷号
21
期号
10
页码范围
1317-1330
出版商
Elsevier
简介
Background
Bortezomib, lenalidomide, and dexamethasone (VRd) is a standard therapy for newly diagnosed multiple myeloma. Carfilzomib, a next-generation proteasome inhibitor, in combination with lenalidomide and dexamethasone (KRd), has shown promising efficacy in phase 2 trials and might improve outcomes compared with VRd. We aimed to assess whether the KRd regimen is superior to the VRd regimen in the treatment of newly diagnosed multiple myeloma in patients who were not being considered for immediate autologous stem-cell transplantation (ASCT).
Methods
In this multicentre, open-label, phase 3, randomised controlled trial (the ENDURANCE trial; E1A11), we recruited patients aged 18 years or older with newly diagnosed multiple myeloma who were ineligible for, or did not intend to have, immediate ASCT. Participants were recruited from 272 community oncology practices or academic …
学术搜索中的文章
SK Kumar, SJ Jacobus, AD Cohen, M Weiss… - The Lancet Oncology, 2020